PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers, Preclinical Services for cGMP Biopharmaceutical Product Development and Manufacturing, and Toxicology and Pharmacology Testing 13
ID: 75N91024D00008 • Type: Award Notice
• Match:
85%
Opportunity Assistant
Loading
Overview
Awardee
Award ID
75N91024D00008
Reported Award
$149,995,000
Award Date
Sept. 13, 2024
Posted
Sept. 16, 2024, 3:24 p.m. EDT
Set Aside
None
Place of Performance
Belmont, CA 94002
United States
Source
Current SBA Size Standard
1000 Employees
Pricing
Cost Plus Fixed Fee
Vehicle Type
Indefinite Delivery Contract
PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers, Preclinical Services for cGMP Biopharmaceutical Product Development and Manufacturing, and Toxicology and Pharmacology Testing (75N91024D00008) was awarded to Curia Bio on 9/16/24 by National Institutes of Health.
Primary Contact
Documents
Posted documents for Award Notice 75N91024D00008
Opportunity Assistant
AI Analysis
Opportunity Lifecycle
Procurement notices related to Award Notice 75N91024D00008
Award Notifications
Agency published notification of awards for Award Notice 75N91024D00008
Similar Active Opportunities
Open contract opportunities similar to Award Notice 75N91024D00008
Experts for PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers, Preclinical Services for cGMP Biopharmaceutical Product Development and Manufacturing, and Toxicology and Pharmacology Testing
Recommended subject matter experts available for hire
Additional Details
Source Agency Hierarchy
HEALTH AND HUMAN SERVICES, DEPARTMENT OF > NATIONAL INSTITUTES OF HEALTH > NIH NCI
FPDS Organization Code
7529-00316
Source Organization Code
100188082
Last Updated
Sept. 28, 2024
Last Updated By
megan.osele@nih.gov
Archive Date
Sept. 28, 2024